Biosimilars: what clinicians should know, Blood, vol.120, pp.5111-5118, 2012. ,
Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists, BioDrugs, vol.31, pp.447-59, 2017. ,
, Open Medic : base complète sur les dépenses de médicaments interrégimes, 2018.
Biosimilars for the management of rheumatoid arthritis: economic considerations, Expert Rev Clin Immunol, vol.11, pp.43-52, 2015. ,
Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK, BioDrugs Clin Immunother Biopharm Gene Ther, vol.31, pp.533-577, 2017. ,
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes, Drugs, vol.78, pp.463-78, 2018. ,
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, doubleblind, non-inferiority trial, The Lancet, vol.389, issue.17, pp.30068-30073, 2017. ,
Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France, PloS One, vol.10, p.117214, 2015. ,
,
, Presse Medicale Paris Fr, vol.46, pp.887-896, 1983.
, World Health Organization. GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS
Les biosimilaires en Médecine Interne : bien les connaître pour bien les prescrire. Rev Médecine Interne, 2018. ,
Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents, Curr Med Res Opin, vol.32, pp.829-863, 2016. ,
Comparison of injection site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a Phase III study, Br J Dermatol, 2017. ,
Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?, Ann Rheum Dis, vol.2017 ,
Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Benucci, Ann Rheum Dis, 2018. ,
Response to: 'Seeing the glass either half full or half empty: response to the correspondence 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?'' by Scherlinger and Schaeverbeke, Ann Rheum Dis, 2018. ,
Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Bennuci, Ann Rheum Dis, 2018. ,
, août 2017 relative aux médicaments biologiques, à leurs similaires ou « biosimilaires, 2017.
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases, Ann Rheum Dis, vol.77, pp.165-74, 2018. ,
Des usagers sceptiques face aux médicaments génériques : une approche anthropologique, Epidemiol Public Health Rev Epidémiologie Santé Publique, vol.55, pp.179-85, 2007. ,
Acceptance Rate And Sociological Factors Involved In The Switch From Originator To Biosimilar Etanercept (SB4). Semin Arthritis Rheum, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01992911
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab, Arthritis Rheumatol, vol.70, pp.60-68, 2018. ,
Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance, Joint Bone Spine, 2017. ,
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study, Ann Rheum Dis, 2016. ,
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study, Ann Rheum Dis, 2016. ,
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect, Rheumatol Ther, vol.4, pp.209-227, 2017. ,
L'effet Nocebo : particularités et conséquences pour le clinicien, Rev Médecine Interne, vol.39, pp.315-335, 2018. ,
The Impact of Biosimilar Competition in Europe, 2017. ,
, INSTRUCTION N° DSS/1C/DGOS/PF2/2018/42 du 19 février 2018 relative à l'incitation à la prescription hospitalière de médicaments biologiques similaires, lorsqu'ils sont délivrés en ville n, 2018.
,
, prévalence et sévérité de la polyarthrite rhumatoïde au XXI e siècle, vol.84, pp.303-313, 2017.
Épidémiologie de la spondyloarthrite au xxie siècle, Rev Rhum Monogr, vol.81, pp.225-234, 2014. ,
Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis, Joint Bone Spine, vol.80, pp.29-33, 2013. ,
OP0015 Mortality of the cobra early rheumatoid arthritis trial cohort after 23 years follow up, Ann Rheum Dis, vol.77, pp.57-57, 2018. ,
Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents, Curr Med Res Opin, vol.32, pp.829-863, 2016. ,
, European Medicines Agency -Multidisciplinary -Similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues n, 2018.
Biosimilars for the management of rheumatoid arthritis: economic considerations, Expert Rev Clin Immunol, vol.11, pp.43-52, 2015. ,
Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK, BioDrugs Clin Immunother Biopharm Gene Ther, vol.31, pp.533-577, 2017. ,
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab, Arthritis Rheumatol, vol.70, pp.60-68, 2018. ,
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Semin Arthritis Rheum, vol.47, pp.741-749, 2018. ,
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect, Rheumatol Ther, vol.4, pp.209-227, 2017. ,
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial, The Lancet, vol.389, issue.17, pp.30068-30073, 2017. ,
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry, Ann Rheum Dis, vol.76, pp.1426-1457, 2017. ,
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes, Drugs, vol.78, pp.463-78, 2018. ,
The Impact of Biosimilar Competition in Europe, 2017. ,
, INSTRUCTION N° DSS/1C/DGOS/PF2/2018/42 du 19 février 2018 relative à l'incitation à la prescription hospitalière de médicaments biologiques similaires, lorsqu'ils sont délivrés en ville n, 2018.
Perception of antiretroviral generic medicines: one-day survey of HIV-infected patients and their physicians in France, PloS One, vol.10, p.117214, 2015. ,
Communication techniques for improved acceptance and adherence with therapeutic footwear, Prosthet Orthot Int, vol.41, pp.201-205, 2017. ,
The nocebo effect: a clinical challenge in the era of biosimilars, Expert Rev Clin Immunol, vol.2018, pp.1-11 ,
, Les médicaments biosimilaires : données de la Nouvelle-Aquitaine, journée régionale de l'OMEDIT Nouvelle-Aquitaine juin 2017